Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 34,523 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the sale, the chief executive officer directly owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Joseph Oliveto also recently made the following trade(s):

• On Monday, December 15th, Joseph Oliveto sold 133,054 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total transaction of $308,685.28.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $1,125.00.

Milestone Pharmaceuticals Price Performance

MIST stock traded down $0.07 during trading on Wednesday, reaching $1.94. 1,697,941 shares of the company were exchanged, compared to its average volume of 3,110,069. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The stock’s 50 day moving average price is $2.23 and its 200 day moving average price is $1.96. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $3.06. The company has a market cap of $165.23 million, a P/E ratio of -2.37 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. As a group, analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Key Headlines Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIST. Propel Bio Management LLC grew its stake in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $6,444,000. Simplify Asset Management Inc. grew its position in shares of Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares during the period. Pathstone Holdings LLC acquired a new position in Milestone Pharmaceuticals in the third quarter valued at $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the third quarter worth about $1,333,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company upped their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Zacks Research raised shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.